XML 42 R31.htm IDEA: XBRL DOCUMENT v3.25.3
Identifiable Intangible Assets, Net and Goodwill (Tables)
 9 Months Ended
Sep. 28, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
September 28, 2025December 31, 2024
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$101,220 $(69,057)$32,163 $99,397 $(65,044)$34,353 
Brands
1,274 (1,023)251 1,277 (992)285 
Licensing agreements and other2,355 (1,256)1,099 2,724 (1,513)1,210 
104,849 (71,337)33,513 103,397 (67,549)35,848 
Indefinite-lived intangible assets
IPR&D(a), (b)
17,350 17,350 18,893 18,893 
Licensing agreements and other(c)
461 461 670 670 
17,811 17,811 19,563 19,563 
Identifiable intangible assets(d)
$122,660 $(71,337)$51,324 $122,961 $(67,549)$55,411 
(a)The changes in the gross carrying amounts primarily reflect the transfer of $600 million and $590 million from IPR&D to developed technology rights for Padcev and talazoparib (Talzenna), respectively, as well as the impact of foreign exchange.
(b)The decrease in the gross carrying amount reflects an impairment of $260 million (see Note 4).
(c)The decrease in the gross carrying amount reflects an impairment of $210 million (see Note 4).
(d)The decrease is primarily due to amortization expense of $3.6 billion.
Schedule of Indefinite Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
September 28, 2025December 31, 2024
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$101,220 $(69,057)$32,163 $99,397 $(65,044)$34,353 
Brands
1,274 (1,023)251 1,277 (992)285 
Licensing agreements and other2,355 (1,256)1,099 2,724 (1,513)1,210 
104,849 (71,337)33,513 103,397 (67,549)35,848 
Indefinite-lived intangible assets
IPR&D(a), (b)
17,350 17,350 18,893 18,893 
Licensing agreements and other(c)
461 461 670 670 
17,811 17,811 19,563 19,563 
Identifiable intangible assets(d)
$122,660 $(71,337)$51,324 $122,961 $(67,549)$55,411 
(a)The changes in the gross carrying amounts primarily reflect the transfer of $600 million and $590 million from IPR&D to developed technology rights for Padcev and talazoparib (Talzenna), respectively, as well as the impact of foreign exchange.
(b)The decrease in the gross carrying amount reflects an impairment of $260 million (see Note 4).
(c)The decrease in the gross carrying amount reflects an impairment of $210 million (see Note 4).
(d)The decrease is primarily due to amortization expense of $3.6 billion.